735 related articles for article (PubMed ID: 25792301)
1. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
[TBL] [Abstract][Full Text] [Related]
3. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Beaver JA; Amiri-Kordestani L; Charlab R; Chen W; Palmby T; Tilley A; Zirkelbach JF; Yu J; Liu Q; Zhao L; Crich J; Chen XH; Hughes M; Bloomquist E; Tang S; Sridhara R; Kluetz PG; Kim G; Ibrahim A; Pazdur R; Cortazar P
Clin Cancer Res; 2015 Nov; 21(21):4760-6. PubMed ID: 26324739
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib: A new hope in the treatment of breast cancer.
Palanisamy RP
J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
[TBL] [Abstract][Full Text] [Related]
6. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
7. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib improves survival in advanced breast cancer.
Burki TK
Lancet Oncol; 2017 Jan; 18(1):e1. PubMed ID: 27890465
[No Abstract] [Full Text] [Related]
9. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Kim ES; Scott LJ
Target Oncol; 2017 Jun; 12(3):373-383. PubMed ID: 28488183
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Masuda N; Nishimura R; Takahashi M; Inoue K; Ohno S; Iwata H; Mori Y; Hashigaki S; Muramatsu Y; Nagasawa T; Umeyama Y; Toi M
Cancer Sci; 2018 Mar; 109(3):803-813. PubMed ID: 29345736
[TBL] [Abstract][Full Text] [Related]
15. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
[TBL] [Abstract][Full Text] [Related]
16. Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
Bromberg DJ; Valenzuela M; Nanjappa S; Pabbathi S
Cancer Control; 2016 Jan; 23(1):59-60. PubMed ID: 27009458
[TBL] [Abstract][Full Text] [Related]
17. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
19. Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Pritchard KI; Chia SK; Simmons C; McLeod D; Paterson A; Provencher L; Rayson D
Oncologist; 2017 Jan; 22(1):12-24. PubMed ID: 27864574
[TBL] [Abstract][Full Text] [Related]
20. Ribociclib: First Global Approval.
Syed YY
Drugs; 2017 May; 77(7):799-807. PubMed ID: 28417244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
